Treace Announces First Annual National Bunion Day
Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone Deformity
PONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the first-ever National Bunion Day in the United States. National Bunion Day is an opportunity to help more people learn about the identification and treatment of this common bone deformity in the foot, which often includes debilitating pain for millions of adults in the U.S. Approximately one in four U.S. adults alone develop the bunion deformity in their lifetime.1
As the leader in 3D bunion correction, Treace is uniquely positioned to drive greater patient education and awareness of the Lapiplasty® procedure, the #1 most commonly used 3D bunion correction procedure chosen by U.S. surgeons.2 As part of National Bunion Day, Treace is sponsoring a broad-based awareness and information campaign to address misconceptions and stigma associated with bunions. The awareness campaign includes a series of new educational materials, online events, opportunities for patients to share their experiences in traditional and social media, and physician outreach. April also marks National Foot Health Awareness Month, an opportunity to set a strong foundation of bunion education and awareness. The month-long effort calls on all followers to stand up against the stigma surrounding bunions, fostering a community of support.
“Since our first surgical cases in 2015, Treace has been committed to developing innovative treatment options for patients living with bunions and other midfoot deformities, but issues in foot health and bunion treatment have remained under the radar despite the fact that they affect millions of people,” said John T. Treace, CEO and Founder of Treace. “Our establishment of National Bunion Day is a reflection of our dedication to the patient communities we serve, and the launch of our new national campaign is designed to erase the stigma and misinformation surrounding bunions and to expand our support for both patients and clinicians through our awareness and educational initiatives. The Lapiplasty® 3D Bunion Correction® Procedure, pioneered by Treace, is designed to minimize recovery time, provide lasting relief from bunion pain, reduce recurrence rates, and improve patient outcomes. We look forward to reaching even more people and raising awareness of the impact that effective bunion treatment can have on the quality of life for patients.”
“Our practice is proud to offer the Lapiplasty® 3D Bunion Correction® Procedure to our patients, who often live with bunion pain for months or even years because of the stigma surrounding the condition,” stated Paul Dayton, DPM, MS, FACFAS, of the Foot & Ankle Center of Iowa and one of the original design surgeons for the Lapiplasty® Procedure.3 “The establishment of National Bunion Day will bring attention to this common and disruptive health issue, educate patients about the latest treatment options that are designed to get them back to the activities they enjoy and dismantle the stigma surrounding this condition.”
Founded by Treace, National Bunion Day will be held each year on the third Tuesday of April. Updates on activities planned for National Bunion Day are available on the official National Bunion Day webpage at www.lapiplasty.com/NationalBunionDay.
Those living with bunion pain are encouraged to speak with their healthcare professional about available treatment plans and whether the Lapiplasty® Procedure is right for them. Individual results and recovery times may vary. More information about the Lapiplasty® Procedure, including benefits, risks, and recovery, is available at https://www.lapiplasty.com/.
About Bunions and the Lapiplasty® 3D Bunion Correction® Procedure
Bunions are complex bone deformities that result from an unstable joint in the midfoot4 and are frequently marked by a large bump on the side of the big toe. While many believe they are caused by wearing high heels or narrow shoes, bunions affect both men and women of all ages and are often caused by genetic factors.4,5 Bunion deformities are progressive and may lead to arthritis, hammertoes, bone spurs, pain, swelling and numbness that may have a significant impact on mobility and quality of life.4,6 Many people may be reluctant to seek treatment for bunions due to common misconceptions surrounding treatment approaches.
The Lapiplasty® 3D Bunion Correction® Procedure allows surgeons to correct all three planes of the bunion deformity and address its root cause by securing the unstable joint in the middle of the foot using a patented combination of instruments, implants and surgical methods. By facilitating a comprehensive, 3D correction of the bunion deformity, the Lapiplasty® Procedure allows most patients to quickly return to bearing weight in a surgical boot within two weeks after surgery and get back to their active lifestyle with a low recurrence rate of only 0.9% to 3.2% as demonstrated in studies at 17- and 13-months follow-up, respectively.7,8
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s expectations that it will reach even more people during National Bunion Day and raise awareness of the impact that effective bunion treatment can have on the quality of life for patients. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook and Instagram.
1 Nix S, et al. J Foot Ankle Res. 2010. 27:3:21.
2 TMC Data on File (AOFAS Member Survey August 2023).
3 Paul Dayton, DPM, is a member of Treace’s Surgeon Advisory Board and a paid consultant for Treace.
4 American College of Foot and Ankle Surgeons (ACFAS) Website
5 WebMD Website
6 American Academy of Orthopedic Surgeons (AAOS) Website
7 Dayton P, et al. J Foot Ankle Surg. 2019. 58:427-433.
8 Ray J, et al. Foot Ankle Int. 2019 Aug;40(8):955-960.
Contacts:
Treace Medical Concepts, Inc.
Julie Dewey, IRC
Chief Communications & Investor Relations Officer
jddewey@treace.com | 209-613-6945
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2d0d0b1a-431e-440f-9da7-2ddbbf022a7d
